An observational study in Coronary Artery Disease, Peripheral Arterial Disease and Atherothrombosis, sponsored by Hospital do Coracao. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-03.
Sponsored by Hospital do Coracao · Observational
NEAT is an observational cohort (Prospective registry of real world data) of patients with coronary and peripheral artery disease in an outopatient setting.
National multicenter registry in Brazil with initial plan of 25 sites from the 5 Brazilian regions. It will be coordinated by HCOR Research Institute which will perform regulatory, data and site management beyond academic leadership.NEAT is an observational cohort (Prospective registry of real world data) of patients with coronary and peripheral artery disease in an outopatient setting with 12 months of follow-up with collection of data at baseline, 6 months and 12 months.
5,598 studies on the registry are indexed under Coronary Artery Disease; 957 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 336 across 1,947 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Hospital do Coracao is the lead sponsor of 66 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with coronary and peripheral arterial disease in an outpatient setting
Patients ≥45 years followed in ambulatory setting with ≥1 of the following 3 criteria:
Documented coronary disease (≥1 criteria must apply):
Documented symptomatic Peripheral Arterial Disease (≥1 criteria must apply):
Exclusion Criteria:
Percentage of patients receiving evidence based therapies to reduce cardiovascular risk
DOMAIN 1: Appropriate use of antithrombotic therapy
Time frame: Baseline
Percentage of patients receiving evidence based therapies to reduce cardiovascular risk
DOMAIN 2: Cholesterol control
Time frame: Baseline
Percentage of patients receiving evidence based therapies to reduce cardiovascular risk
DOMAIN 3: Blood pressure control
Time frame: Baseline
Percentage of patients receiving evidence based therapies to reduce cardiovascular risk
DOMAIN 4: Glycemic control / diabetes treatment
Time frame: Baseline
Percentage of patients receiving evidence based therapies to reduce cardiovascular risk
DOMAIN 5: Weight control
Time frame: Baseline
Percentage of patients receiving evidence based therapies to reduce cardiovascular risk
DOMAIN 6: Non-pharmacological intervention: In this domain, there are 2 items to be evaluated: 1) No smoking; 2) Physical exercise ≥ 150 minutes per week.
Time frame: Baseline
Percentage of patients receiving complete evidence based therapies to reduce cardiovascular risk
Patient should receive all of the following to consider complete evidence based therapy: Appropriate use of antithrombotic therapy; Cholesterol control; Blood pressure control; Glycemic control / diabetes treatment; Weight control; Non-pharmacological intervention
Time frame: 6 and 12 months
Percentage of patients with complete control of risk factors (blood pressure, cholesterol and glycemia)
blood pressure, cholesterol and glycemia levels at baseline, 06 and 12 months
Time frame: baseline, 06 and 12 months
This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital do Coracao